唑来膦酸对绝经后女性血脂及骨量的影响

目的:探讨5 mg唑来膦酸对绝经后女性血脂和骨量的影响.方法 :103例绝经后骨质疏松症病人随机分为2组,治疗组53例,静脉滴注唑来膦酸5 mg,每年1次,口服钙尔奇D 600 mg,每日1次,阿法D30.25μg,每日1次;对照组50例,口服钙尔奇D 600 mg,每日1次,阿法D30.25μg,每日1次.连续治疗12个月后,比较2组治疗前后骨密度及血脂变化.结果 :经治疗12个月后,治疗组腰椎L2~4、Ward三角、股骨近端总骨矿物质密度较对照组高,治疗组总胆固醇、低密度脂蛋白胆固醇较对照组低(P<0.05);2组血三酰甘油、高密度脂蛋白胆固醇差异无统计学意义(P>0.05).结论 :绝经后骨质疏松症病人经过5 mg唑来膦酸治疗,腰椎L2~4及股骨近端骨密度显著提高,血脂明显降低.

Effect of zoledronic acid on blood lipid and bone mineral density in postmenopausal females

Objective:To study the effects of zoledronic acid on blood lipid and bone mineral density(BMD),and the relationship between blood lipid and BMD. Methods:One hundred and three postmenopausal osteoporosis patients were randomly divided into the treatment group(53 cases) and control group(50 cases). The treatment group was treated with 5 mg of zoledronic acid by intravenous infusionin one time 1 year,600 mg of caltrate D daily and 0. 25μg of alfacalcidol D3 daily for 12 months. The control group was treated with 600 mg of caltrate D daily and 0. 25μg of alfacalcidol D3 daily for 12 months. The levels of the bone density and blood lipid before and after treatment between two groups were compared. Results:After 12 months of treatment, the total bone density of L2-4 , ward triangle and proximal femur in treatment group were higher than those in control group(P<0. 05),and the levels of cholesterol and in treatment group were lower than those in control group(P<0. 05). The differences of the levels of triacylglycerol and between two groups were not statistically significant after treatment(P>0. 05). Conclusions:After the treatment of postmenopausal osteoporosis with 5mg of zoledronic acid,the BMD of lumbar vertebrae and proximal femur of osteoporosis patients obviously increases,and the blood lipid markedly decreases.